• 中国精品科技期刊
  • 《中文核心期刊要目总览》收录期刊
  • RCCSE 中国核心期刊(5/114,A+)
  • Scopus收录期刊
  • 美国《化学文摘》(CA)收录期刊
  • WHO 西太平洋地区医学索引(WPRIM)收录期刊
  • 《中国科学引文数据库(CSCD)》核心库期刊 (C)
  • 中国科技核心期刊
  • 中国科技论文统计源期刊
  • 《日本科学技术振兴机构数据库(中国)》(JSTChina)收录期刊
  • 美国《乌利希期刊指南》(UIrichsweb)收录期刊
  • 中华预防医学会系列杂志优秀期刊(2019年)

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

流行病学研究中的样本代表性问题(二)

潘雄飞 王意 叶依 潘安

潘雄飞, 王意, 叶依, 潘安. 流行病学研究中的样本代表性问题(二)[J]. 中华疾病控制杂志, 2019, 23(2): 125-128. doi: 10.16462/j.cnki.zhjbkz.2019.02.001
引用本文: 潘雄飞, 王意, 叶依, 潘安. 流行病学研究中的样本代表性问题(二)[J]. 中华疾病控制杂志, 2019, 23(2): 125-128. doi: 10.16462/j.cnki.zhjbkz.2019.02.001
PAN Xiong-fei, WANG Yi, YE Yi, PAN An. Representativeness issues in epidemiological studies (Ⅱ)[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2019, 23(2): 125-128. doi: 10.16462/j.cnki.zhjbkz.2019.02.001
Citation: PAN Xiong-fei, WANG Yi, YE Yi, PAN An. Representativeness issues in epidemiological studies (Ⅱ)[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2019, 23(2): 125-128. doi: 10.16462/j.cnki.zhjbkz.2019.02.001

流行病学研究中的样本代表性问题(二)

doi: 10.16462/j.cnki.zhjbkz.2019.02.001
详细信息
    通讯作者:

    潘安, E-mail: panan@hust.edu.cn

  • 中图分类号: R181

Representativeness issues in epidemiological studies (Ⅱ)

More Information
  • 摘要: 本文针对流行病学研究中多中心干预设计、效应异质性、应答率、失访率等问题,深入分析了其与样本代表性的关系。同时,针对当前精准医学和基于大数据流行病学研究的发展趋势,讨论了样本代表性问题的现实意义。总而言之,人群健康研究工作者应正确认识样本代表性在流行病学研究中的作用和地位,科学合理设计研究以获得最佳证据。
  • [1] Robertson D, Williams GH. Clinical and translational science: principles of human research[J]. Academic Press, 2009. http://www.martinsfontespaulista.com.br/clinical-and-translational-science-principles-of-human-research-271737.aspx/p
    [2] Appel LJ. A primer on the design, conduct, and interpretation of clinical trials[J]. Clin J Am Soc Nephrol, 2006, 1(6): 1360-1367. DOI: 10.2215/CJN.02850806.
    [3] Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?"[J]. Lancet, 2005, 365(9453): 82-93. DOI: 10.1016/S0140-6736(04)17670-8.
    [4] Rothwell PM. Factors that can affect the external validity of randomised controlled trials[J]. PLoS Clin Trials, 2006, 1(1): e9. DOI: 10.1371/journal.pctr.0010009.
    [5] Mishra D, Vora J. Non interventional drug studies in oncology: Why we need them?[J]. Perspect Clin Res, 2010, 1(4): 128-133. DOI: 10.4103/2229-3485.71770.
    [6] Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence - what is it and what can it tell us?[J]. N Engl J Med, 2016, 375(23): 2293-2297. DOI: 10.1056/NEJMsb1609216.
    [7] 唐金陵, 杨祖耀. 观察与实验效力与效果[J]. 中华流行病学杂志, 2014, 35(3): 221-227. DOI: 10.3760/cma.j.issn.0254-6450.2014.03.001.

    Tang JL, Yang ZY. Observation versus experiment, efficacy versus effectiveness[J]. Chin J Epidemiol, 2014, 35(3): 221-227. DOI: 10.3760/cma.j.issn.0254-6450.2014.03.001.
    [8] Stang A, Jockel KH. Avoidance of representativeness in presence of effect modification[J]. Int J Epidemiol, 2014, 43(2): 630-631. DOI: 10.1093/ije/dyt263.
    [9] Rothman K, Hatch E, Gallacher J. Representativeness is not helpful in studying heterogeneity of effects across subgroups[J]. Int J Epidemiol, 2014, 43(2): 633-634. doi: 10.1093/ije/dyt265
    [10] Kristman V, Manno M, Cote P. Loss to follow-up in cohort studies: how much is too much?[J]. Eur J Epidemiol, 2004, 19(8): 751-760. DOI: 10.1023/B:EJEP.0000036568.02655.f8.
    [11] Stang A. Nonresponse research——an underdeveloped field in epidemiology[J]. Eur J Epidemiol, 2003, 18(10): 929-931. http://europepmc.org/abstract/MED/14598921
    [12] Cole SR, Platt RW, Schisterman EF, Chu H, Westreich D, Richardson D, Poole C. Illustrating bias due to conditioning on a collider[J]. Int J Epidemiol, 2010, 39(2): 417-420. DOI: 10.1093/ije/dyp334.
    [13] Tripepi G, Jager KJ, Dekker FW, et al. Selection bias and information bias in clinical research[J]. Nephron Clin Pract, 2010, 115(2): c94-99. DOI: 10.1159/000312871.
    [14] Nohr EA, Frydenberg M, Henriksen TB, et al. Does low participation in cohort studies induce bias?[J]. Epidemiology, 2006, 17(4): 413-418. DOI: 10.1097/01.ede.0000220549.14177.60.
    [15] Manolio TA, Collins R. Enhancing the feasibility of large cohort studies[J]. JAMA, 2010, 304(20): 2290-2291. DOI: 10.1001/jama.2010.1686.
    [16] Manolio TA, Weis BK, Cowie CC, et al. New models for large prospective studies: is there a better way?[J]. Am J Epidemiol, 2012, 175(9): 859-866. DOI: 10.1093/aje/kws409.
    [17] Manolio TA, Collins R, National Institutes of Health New Models Workshop Participants. Vehement agreement on new models?[J]. Am J Epidemiol, 2013, 177(4): 290-291. DOI: 10.1093/aje/kws410.
    [18] Chen Z, Lee L, Chen J, et al. Cohort profile: the Kadoorie study of chronic disease in China (KSCDC)[J]. Int J Epidemiol 2005, 34(6): 1243-1249. DOI: 10.1093/ije/dyi174.
    [19] Chen Z, Chen J, Collins R, et al. China Kadoorie biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up[J]. Int J Epidemiol, 2011, 40(6): 1652-1666. DOI: 10.1093/ije/dyr120.
    [20] Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med, 2015, 12(3): e1001779. DOI: 10.1371/journal.pmed.1001779.
    [21] Kuehn BM. Study recruitment to accelerate precision medicine[J]. JAMA, 2018, 319(4): 332. http://europepmc.org/abstract/MED/29362781
    [22] Schmidt C. The Death of a Study. A long-term study of childhood disease burned through 1.3 billion in taxpayer funds, only to be mothballed before it ever got off the ground. Why?[EB/OL]. (2016-5-25)[2018-6-19]. qhttps://undark.org/article/the-death-of-a-study-national-childrens-study/
    [23] Rothman KJ, Gallacher JE, Hatch EE. Why representativeness should be avoided[J]. Int J Epidemiol, 2013, 42(4): 1012-1014. DOI: 10.1093/ije/dys223.
    [24] Zhan Q, Qian H. Opportunities and advantages for the development of precision medicine in China[J]. Science/AAAS Custom Publishing Office, Precision medicine in China Washington, DC: Science/AAAS 2016: 6. doi: 10.1186/s13073-016-0388-7
    [25] Thygesen LC, Ersboll AK. When the entire population is the sample: strengths and limitations in register-based epidemiology[J]. Eur J Epidemiol, 2014, 29(8): 551-558. DOI: 10.1007/s10654-013-9873-0.
    [26] 唐金陵, 李立明. 关于循证医学、精准医学和大数据研究的几点看法[J]. 中华流行病学杂志, 2018, 39(1): 1-7. DOI: 10.3760/cma.j.issn.0254-6450.2018.01.001.

    Tang JL, Li LM. Some reflections on evidenced-based medicine, precision medicine, and big data-based research[J]. Chin J Epidemiol, 2018, 39(1): 1-7. DOI: 10.3760/cma.j.issn.0254-6450.2018.01.001.
  • 加载中
计量
  • 文章访问数:  607
  • HTML全文浏览量:  292
  • PDF下载量:  92
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-12-26
  • 刊出日期:  2019-02-10

目录

    /

    返回文章
    返回